NEW YORK, April 20, 2020 -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX).
This marks the third CIR payment AzurRx SAS has received in 2020. Since March including the 2019 CIR, the Company has received approximately $2.52 million in non-dilutive funding in research tax credits from the French government.
Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx’s Phase 2 Clinical Study for MS1819-SD,.
“Greg is a strong and welcomed addition to our board,” said James Sapirstein, CEO of AzurRx BioPharma. "I am excited to join the AzurRx Board with its compelling potential synthetic alternative to PERT therapy,” said Mr. Oakes. “I look forward to helping the Company realize the full commercial potential of the MS1819 program."
BROOKLYN, NY / ACCESSWIRE / April 15, 2020 / AzurRx BioPharma, Inc. (NASDAQ:AZRX), is a clinical stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of ...
The French R&D tax credit initiative (“Crédit d’Impôt Recherche”, or CIR) gives eligible research-based French companies, which are subject to corporate tax in France, the ability to claim tax relief of up to 30% on costs incurred in R&D activities. “The 30% tax relief on R&D activities provides a significant non-dilutive funding source for our on-going research and clinical trial activities in France and Europe through our AzurRx SAS subsidiary,” said James Sapirstein, the CEO of AzurRx. The Research Tax Credit (CIR) is a tax incentive provided by the French Government to encourage the growth of businesses' competitiveness by favoring research and development (R&D) and innovative activities.
Alexander Capital, LP acted as sole placement agent in the Offering. Net proceeds from the Offering will be used to eliminate short- and long-term indebtedness, and for general working capital purposes, including product development. The Offering consisted of Senior Convertible Promissory Notes (the “Notes”) and warrants (the “Warrants”) to purchase shares of the Company’s common stock (the “Common Stock”).
BROOKLYN, N.Y., Jan. 06, 2020 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant.
By John Vandermosten, CFA NASDAQ:AZRX Infectious Disease With the concerns related to the emergence of the novel coronavirus in the news on a daily basis, attention to animal-sourced product used in medicines has also come in to focus. Fears are also rising related to the transmission of animal viruses passing to humans, similar to what happened in the Avian Flu outbreaks from 2013 to 2017 in
In March 2020, the Company announced it had received $1.13 million for its 2018 CIR for an aggregate total of $1.77 million in non-dilutive funding received in 2020. In addition, the Company anticipates it will receive the 2019 CIR payment by the end of 2020. The CIR has been used to fund AzurRx’s ongoing MS1819 clinical trials, including its Phase 2 Combination therapy study in Cystic Fibrosis.
On track to initiate the OPTION 2 trial by the end of Q2 2020OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsulesTrial.
Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they underperformed ...
By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its 2019 10-K with the SEC for the twelve month period ending December 31, 2019. Highlights for the reporting period and to date include the readout from the OPTION trial, the acquisition of global commercialization rights for MS-1819, the launch of a new combination trial for
The presentation, entitled: “Results from a Phase 2, Open-Label, Multicenter, 2x2 Cross-over Trial to Assess the Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,” will be delivered by Dr. Michael Konstan, Vice Dean for Translational Research and Professor of Pediatrics at Case Western Reserve University in Cleveland, Ohio. Dr. Konstan will discuss the data from the Company’s Phase II study of MS1819 in patients with cystic fibrosis, which demonstrated safety, a coefficient of fat absorption (CFA) which was similar to the value at the same dose in a prior study in chronic pancreatitis, and positive unexpected findings on the coefficient of nitrogen absorption (CNA).
Anyone researching AzurRx BioPharma, Inc. (NASDAQ:AZRX) might want to consider the historical volatility of the share...
Under the terms of the agreement, Creapharm will package, label, provide qualified person (QP) release and distribute AzurRx’s MS1819 clinical trial drug product for both the upcoming Phase 2b OPTION 2 Monotherapy and the ongoing Phase 2 Combination Therapy clinical trials for the treatment of EPI in patients with Cystic Fibrosis (CF). MS1819 clinical trial drug supply will be sent directly to clinical sites in the U.S. and in Europe, including, Poland, Hungary, Spain and Turkey from Creapharm’s U.S. and European depots, respectively.
Under the terms of the agreement, Delpharm will manufacture AzurRx’s MS1819 cGMP batch that will be used in the Phase 2b OPTION 2 Clinical Trial for the treatment of EPI in patients with Cystic Fibrosis (CF). As preparation for the cGMP batch, the drug product manufacturing process was transferred to Delpharm and they have successfully produced a non-GMP batch.
IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the.
Anyone researching AzurRx BioPharma, Inc. (NASDAQ:AZRX) might want to consider the historical volatility of the share...
AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer. When I last wrote to you six months ago (on October 22, 2019), as the newly appointed President and CEO of AzurRx, I spoke about my strong belief in the potential of MS1819, our focus on building shareholder value and in raising sufficient capital to achieve our milestones. Despite COVID-19, we currently anticipate only minor delays in initiating and completing our dose-escalating Phase 2 OPTION 2 monotherapy clinical trial, using 2.2g and 4.4g doses of MS1819 in enteric capsules in the U.S. and Poland.
NEW YORK, NY / ACCESSWIRE / March 18, 2020 / AzurRx BioPharma (NASDAQ:AZRX) will be presenting at this year's Spring Investor Summit on March 25 th -26 th . During the current climate of concern, The Spring ...